1. Home
  2. ANVS vs MCHX Comparison

ANVS vs MCHX Comparison

Compare ANVS & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.20

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

HOLD

Current Price

$1.28

Market Cap

67.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANVS
MCHX
Founded
2008
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
67.3M
IPO Year
2019
2003

Fundamental Metrics

Financial Performance
Metric
ANVS
MCHX
Price
$1.20
$1.28
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $10.50
N/A
AVG Volume (30 Days)
★ 1.1M
43.9K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 39.39
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $90,291,000.00
Revenue This Year
N/A
$17.69
Revenue Next Year
N/A
$29.82
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.04
$1.15
52 Week High
$5.50
$2.04

Technical Indicators

Market Signals
Indicator
ANVS
MCHX
Relative Strength Index (RSI) 38.01 38.24
Support Level $1.04 $1.15
Resistance Level $2.43 $1.61
Average True Range (ATR) 0.09 0.11
MACD 0.02 0.01
Stochastic Oscillator 38.46 48.57

Price Performance

Historical Comparison
ANVS
MCHX

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

Share on Social Networks: